Nautilus Biotechnology, Inc. — Form SCHEDULE 13D/A
Filed August 28, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
AH Bio Fund II, L.P. (based in Menlo Park, CA) filed an amended Schedule 13D/A on August 28, 2026 regarding beneficial ownership in Nautilus Biotechnology, Inc. The filing document itself contains no specific dollar amounts, share counts, percentages, or details of what changed from the original filing—only administrative header information and filer/subject company identities are provided in the accessible text.
Why this rating
Amendment filing lacks concrete ownership data; cannot assess materiality without knowing stake size or change. Routine disclosure amendment.
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.